Accuray (NASDAQ:ARAY) versus CELLECT BIOTECH/S (NASDAQ:APOP) Critical Contrast
Accuray (NASDAQ:ARAY) and CELLECT BIOTECH/S (NASDAQ:APOP) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, earnings, analyst recommendations, dividends, institutional ownership, valuation and risk.
Institutional & Insider Ownership
81.2% of Accuray shares are owned by institutional investors. Comparatively, 10.4% of CELLECT BIOTECH/S shares are owned by institutional investors. 3.4% of Accuray shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
This is a breakdown of current ratings for Accuray and CELLECT BIOTECH/S, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Accuray presently has a consensus target price of $4.95, indicating a potential upside of 37.12%. CELLECT BIOTECH/S has a consensus target price of $12.00, indicating a potential upside of 2,207.69%. Given CELLECT BIOTECH/S’s stronger consensus rating and higher probable upside, analysts plainly believe CELLECT BIOTECH/S is more favorable than Accuray.
Valuation & Earnings
This table compares Accuray and CELLECT BIOTECH/S’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Accuray||$404.90 million||0.78||-$23.89 million||($0.28)||-12.89|
|CELLECT BIOTECH/S||N/A||N/A||-$5.37 million||N/A||N/A|
CELLECT BIOTECH/S has lower revenue, but higher earnings than Accuray.
Volatility and Risk
Accuray has a beta of 1.86, meaning that its share price is 86% more volatile than the S&P 500. Comparatively, CELLECT BIOTECH/S has a beta of 1.71, meaning that its share price is 71% more volatile than the S&P 500.
This table compares Accuray and CELLECT BIOTECH/S’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Accuray beats CELLECT BIOTECH/S on 6 of the 10 factors compared between the two stocks.
Accuray Company Profile
Accuray Incorporated designs, develops, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body. The company offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body. The CyberKnife System automatically tracks, detects, and corrects for tumor and patient movement in real-time during the procedure, as well as enables the delivery of precise, high dose radiation while patients breathe normally. It also offers the TomoTherapy System, which consists of an integrated and versatile radiation therapy system used for the treatment of a range of cancer types. The company markets its products in the United States directly, as well as through a sales agent and group purchasing organizations; and directly and through distributors and sales agents in Europe, Japan and other countries of Asia, South America, and internationally to hospitals and stand-alone treatment facilities. Accuray Incorporated was incorporated in 1990 and is headquartered in Sunnyvale, California.
CELLECT BIOTECH/S Company Profile
Cellect Biotechnology Ltd., a biotechnology company, engages in developing ApoGraft, a technology platform that functionally selects stem cells to enhance the safety of regenerative medicine and stem cell therapies in Israel. It is developing the ApoTainer selection kit, a shelf stem cell selection kit for allogeneic hematopoietic stem cell transplantation procedures for patients suffering from hematological malignancies. The company has collaborations with the denovoMATRIX group of the Technische Universität Dresden to conduct examinations into the tentative synergy between ApoGraft and denovoMAtrix technology for the purpose of evaluating collaborative development of products for regenerative medicine; and Cell2in Inc. to conduct scientific evaluations combining ApoGraft with Cell2in's identification technology FreSHtracer, which monitors stem cell quality by utilizing a fluorescent dye to characterize their oxidative stress state. It also has a collaboration with the Washington University School of Medicine to determine the safety and tolerability of ApoGraft for bone marrow transplantations in the United States. The company was formerly known as Cellect Biomed Ltd. and changed its name to Cellect Biotechnology Ltd. in July 2016. Cellect Biotechnology Ltd. was founded in 2011 and is headquartered in Kfar Saba, Israel.
Receive News & Ratings for Accuray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accuray and related companies with MarketBeat.com's FREE daily email newsletter.